GERON CORPORATION (NASDAQ:GERN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
Geron Corporation (the Company or Geron) will be providing
financial information about the Companys cash and investment
balances as of December 31, 2016 in the Companys presentation
handout to be utilized in various meetings with securities
analysts and investors during the J.P. Morgan 35th
Annual Healthcare Conference in San Francisco, California, from
January 9, 2017 through January 12, 2017. The aforementioned
financial information is included on slide #3 of the presentation
handout, as furnished in Exhibit 99.1 to this Current Report, and
is incorporated herein by reference.
The information contained in this Item 2.02 and in the
accompanying Exhibit 99.1 to this Current Report shall be deemed
to be furnished and shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that Section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended (the Securities Act). The information contained
in this Item 2.02 and in the accompanying Exhibit 99.1 to this
Current Report shall not be incorporated by reference into any
filing made by the Company with the U.S. Securities and Exchange
Commission under the Securities Act or the Exchange Act, whether
made before or after the date hereof, regardless of any general
incorporation language in such filing.
Item 7.01 Regulation FD Disclosure.
Geron will participate in various meetings with securities
analysts and investors during the J.P. Morgan 35th
Annual Healthcare Conference in San Francisco, California, from
January 9, 2017 through January 12, 2017 and will utilize a
presentation handout during those meetings. The presentation
handout, together with a slide setting forth certain cautionary
language intended to qualify the forward-looking statements
included in the presentation handout, is furnished as Exhibit
99.1 to this Current Report and is incorporated herein by
reference. The presentation handout will also be made available
in the Investor Relations section of Gerons website, located at
www.geron.com.
The information contained in this Item 7.01 and in the
accompanying Exhibit 99.1 to this Current Report shall be deemed
to be furnished and shall not be deemed to be filed for purposes
of Section 18 of the Exchange Act, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act. The information contained in this Item 7.01 and
in the accompanying Exhibit 99.1 to this Current Report shall not
be incorporated by reference into any filing made by the Company
with the U.S. Securities and Exchange Commission under the
Securities Act or the Exchange Act, whether made before or after
the date hereof, regardless of any general incorporation language
in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||
| 99.1 | January 2017 corporate presentation handout. |
|||
About GERON CORPORATION (NASDAQ:GERN)
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat exhibits relatively preferential inhibition of the clonal proliferation of malignant progenitor cells in nonclinical studies. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. GERON CORPORATION (NASDAQ:GERN) Recent Trading Information
GERON CORPORATION (NASDAQ:GERN) closed its last trading session down -0.08 at 2.23 with 2,499,302 shares trading hands.
